Find your Lawyer

Covid-19 update: Business as usual at Bolt Burdon Kemp

Bolt Burdon Kemp continues to remain very much open for business. We are passionate about achieving life-changing results for our clients, providing excellent client care and ensuring you receive the support you need.

We continue to progress our clients’ existing cases and support new clients with their cases.

All of our wonderful people are successfully working from home. We have re-opened our office so that those who need to work in the office are able to do so, in a socially distanced and safe manner. 

Our strategy of working in teams continues to ensure there is always someone for you to talk to. We are using telephone and video-conferencing very effectively. A number of multi-million pound cases have settled since the virus outbreak, using these facilities.

We are determined more than ever that the wheels of justice will keep on turning.

Contact us on 020 7288 4800 or info@boltburdonkemp.co.uk and one of our team will get in touch with you.

Read more from Managing Partner, Jonathan Wheeler

Round the clock support
Won't shy away from difficult cases
Committed to swiftly progressing claims

A Blood Test for Cancer?

Cancer diagnosis and treatment could be “revolutionised” by a new low-cost blood test which allows doctors to track genetic changes in tumour cells. The “liquid biopsy” test identifies defective fragments of DNA shed into the bloodstream by cancer cells as they die.

Scientists have already used it to detect genetic faults involved in tumour growth in blood samples from 20 women with ovarian cancer. They were also able to build a “real time” picture of how one woman’s breast cancer responded to treatment over more than a year.

Study leader Dr Nitzan Rosenfeld, from Cancer Research UK’s Cambridge Research Institute, said: “This type of blood test has the potential to revolutionise the way we diagnose and treat cancer. The great advantage is that it can be used to identify cancer mutations without surgery or a biopsy, making it safer and cheaper.”

In future, patients could be given treatments based on the result of a quick blood test, rather than having a tissue sample surgically removed for analysis.

The test is said to overcome a major drawback of tumour biopsies, which may provide only a limited snapshot of the genetic mutations present in cancer.

Suzanne is a Partner and is head of the clinical negligence department.

Some of Our Accreditations

See more of our accreditations

We’re here to help you.

Want to talk to one of our experienced lawyers? We can call when it suits you for a no-obligation, strictly confidential chat.

Your browser is out of date. Please update your browser.

This site (and many others) provides a limited experience on unsupported browsers and not all functionality will work correctly or look its best.